Was PolyMASC's early demise self-inflicted
Article Abstract:
The recent merger of Burlinghame, CA-based Valentis with London, UK-based polymer coating firm PolyMASC has prompted speculation as to why PolyMASC ran out of money. This does not usually happen to biotechnology companies. The author seems to think that the company made a mistake in using an IPO as a means of raising money instead of appealing to venture capital companies where advice comes with the investment.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Differentiation and integration
Article Abstract:
Many biotechnology mergers appeared to be the acts of desperation. "Management complementarity" and "technology fit" were the buzz words associated with mergers and acquisitions.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
Gene therapy buy
Article Abstract:
Seattle, WA-based gene therapy specialist Targeted Genetics will buy Philadelphia, PA-based like company Genovo in a stock swap valued at almost $90 million.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: A yeast two-hybrid system for discerning differential interactions using multiple baits. Myogenic expression of an injectable protease-resistant growth hormone-releasing hormone augments long-term growth in pigs
- Abstracts: Are unsolicited credit ratings lower? International evidence from bank ratings. An empirical analysis of the bias and rationality of profit forecasts published in new issue prospectuses
- Abstracts: UH researcher files transgenesis suit. Biotechnology in the Baltic
- Abstracts: A new harvest of fluorescent proteins. Europe makes way into structural biology
- Abstracts: Five stages of the Human Genome project. Going for the big one: blockbuster patents enrich university coffers, but can also affect future patenting and research divisions